Condition
Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations
Total Trials
1
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
Treatment Research
1 treatments under study, led by Tyra300
Related Conditions
Often studied with 14 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 1 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Phase 1/2 (1)
Trial Status
Active Not Recruiting1
Clinical Trials (1)
Research Network
Common Treatments
- Tyra3001
Active Sponsors
- Tyra Biosciences, Inc1
Top Investigators
Tyra Biosciences, Inc
Related Conditions
- Advanced Solid Tumor1
- Bladder Cancer1
- Urinary Tract Cancer1
- Urinary Tract Tumor1
- Solid Tumor1